Skip to content

Medical emergency? What to do

New drugs, deals seen boosting biotech in 2006

3-RXPublished February 21, 20064 min read

Key points

  • The biotechnology sector looks set to grow again in 2006, helped by new drug approvals, a relative lack of generic competition and the eagerness of big drug companies to partner with -- or acquire -- those with products at early stages of development, analysts said.
  • Over the next three days executives from more than 30 biotechnology companies will discuss the future of their new products, the potential for collaborations, and the regulatory environment at the Reuters Biotechnology Summit to be held in London, Boston and Los Angeles.
  • That gap could narrow, though, as big drug companies, which once focused on deals with companies who had products in the late stages of development, seek out smaller, cheaper products, to boost their ailing drug pipelines.
  • Picking the winners among the smaller companies will, as always, be a challenge.

The biotechnology sector looks set to grow again in 2006, helped by new drug approvals, a relative lack of generic competition and the eagerness of big drug companies to partner with -- or acquire -- those with products at early stages of development, analysts said.

"It's been about three years since biotech bottomed out, and this bull period feels much more controlled and sustainable than others," said Eric Schmidt, an analyst at SG Cowen & Co.

Over the next three days executives from more than 30 biotechnology companies will discuss the future of their new products, the potential for collaborations, and the regulatory environment at the Reuters Biotechnology Summit to be held in London, Boston and Los Angeles.

Last year the American Stock Exchange Biotechnology Index <.BTK>, which includes the biggest biotech stocks, rose 25 percent. The broader Nasdaq Biotechnology Index <.NBI> rose just 3 percent.

That gap could narrow, though, as big drug companies, which once focused on deals with companies who had products in the late stages of development, seek out smaller, cheaper products, to boost their ailing drug pipelines.

"I think this may a year when small and mid-cap companies do well," said Daniel Omstead, chief executive officer of Hambrecht & Quist Capital Management LLC. "You're starting to see big pharmaceutical companies do deals with the little companies for more than just late-stage products."

Picking the winners among the smaller companies will, as always, be a challenge.

"While our macro view is bullish on small-cap biotech for 2006, we do not recommend indiscriminate buying," said Joel Sendek, an analyst at Lazard Capital Markets.

Sendek said certain stocks that declined in value despite the 2005 run-up may be set to rebound in 2006, including OSI Pharmaceuticals Inc. and MGI Pharma Inc. .

Global biotechnology sales are expected to rise 13 percent to 14 percent in 2006, driven by new product introductions and the growth of existing products, according to IMS Health, a pharmaceutical information and consulting company.

While almost everyone involved in biotechnology has had their share of heartaches, few disappointments were as spectacular as the withdrawal last year by Biogen Idec Inc. and Elan Corp. Plc of multiple sclerosis drug Tysabri after three patients contracted a rare brain disease.

A closely watched event this year will be whether U.S. regulators will allow the product -- which analysts had once expected to be a blockbuster -- back to the market. Optimism grew earlier this month when the U.S. Food and Drug Administration said the company could resume clinical trials in patients who had previously been receiving the drug.

The decision is important not just for the companies involved but as a barometer of the FDA's attitude toward risk, which tightened considerably after Merck & Co. withdrew its painkiller Vioxx but may be loosening slightly now.

"Public concern over drug safety issues is waning and new drug approvals have occurred in a relatively timely and transparent fashion," said Schmidt, in a report.

More than 25 products could be approved this year in the U.S. alone, including panitumumab, a colorectal drug from Amgen ; telbivudine, a hepatitis B drug from Idenix Pharmaceuticals Inc. ; indiplon, an insomnia treatment from Neurocrine Biosciences Inc. ; and Lucentis, a drug for wet age-related macular degeneration from Genentech Inc. , which is majority owned by Roche Holding AG .

Genzyme Corp. expects to hear within the next two months whether European and U.S. regulators will approve its drug Myozyme for Pompe disease, a debilitating and often fatal muscular disorder.

In Europe, where the industry is less mature, investors are also awaiting some pivotal news, with Belgium's UCB set to file Cimzia for Crohn's disease and Spain's Zeltia due to resubmit cancer drug Yondelis.

Stephen McGarry of Goldman Sachs in London believes consolidation could drive the sector in Europe this year, as companies with cash or strong valuations seek to broaden their portfolios through acquisitions.

Many biotech companies remain loss-making -- particularly in Europe -- but as more products progress to market, more businesses should move into the black.

The average profitable U.S. biotechnology company trades at about 30 times 2006 expected earnings, Schmidt said, roughly in line with historical levels.

"We believe this multiple is sustainable and expect the average large company to appreciate in line with the industry's 15 percent to 20 percent growth rate," he said.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.